Lipid Formulations with Immunogens
GlaxoSmithKline Biologicals S.A.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 9 of these applications claim priority to application 13/808,080, filed Mar 14, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,638,693 | Vaccine for Eliciting Immune Response Comprising RNA Encoding an Immunogen and Lipid Formulations Comprising Mole Percentage of Lipids In force · Medium confidence UsedRemaining | GlaxoSmithKline Biologicals S.A. | In force | Medium confidence | ||
| US 11,638,694 | Vaccine for Eliciting Immune Response Comprising Lipid Formulations and RNA Encoding Multiple Immunogens In force · Medium confidence | GlaxoSmithKline Biologicals S.A. | In force | Medium confidence | ||
| US 11,666,534 | Methods of Administering Lipid Formulations with Viral Immunogens In force · Low confidence | GlaxoSmithKline Biologicals S.A. | In force | Low confidence | ||
| US 11,766,401 | Methods of Administering Lipid Formulations with Immunogens In force · High confidence | GlaxoSmithKline Biologicals S.A. | In force | High confidence | ||
| US 11,786,467 | Lipid Formulations with Immunogens In force · Low confidence | GlaxoSmithKline Biologicals S.A. | In force | Low confidence | ||
| US 11,839,686 | Lipid Formulations with Viral Immunogens In force · High confidence | GlaxoSmithKline Biologicals S.A. | In force | High confidence | ||
| US 11,857,681 | Lipid Formulations with RNA Encoding Immunogens In force · Medium confidence | GlaxoSmithKline Biologicals S.A. | In force | Medium confidence | ||
| US 11,883,534 | Immunisation with Lipid Formulations with RNA Encoding Immunogens In force · Medium confidence | GlaxoSmithKline Biologicals S.A. | In force | Medium confidence | ||
| US 11,850,305 | Method of Making Lipid Formulations with RNA Encoding Immunogens In force · Medium confidence | GlaxoSmithKline Biologicals S.A. | In force | Medium confidence | ||
| Application 13/808,080 | Liposomes with Lipids Having an Advantageous Pka-Value for RNA Delivery Abandoned Abandoned Jan 13, 2023 | GlaxoSmithKline Biologicals S.A. | Abandoned | Abandoned Jan 13, 2023 | ||
| 5 more records in this group · Pro | ||||||
10 of 15 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 15.
9 of these are in force and held by GlaxoSmithKline Biologicals S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.